Dr. Ted Rothstein

USA

Neuroanatomic changes associated with 55 consecutive long-term post COVID-19 patients with cognitive deficits

Dr. Bram Palache

Netherlands

Disparities in Seasonal Influenza Vaccination in Europe

Dr. Airi Poder

Estonia

Recruitment Strategies for Vaccine Trials in Areas of Low Population Density

Ping Wu

USA

Antiviral and immunomodulatory effects of ouabain against congenital Zika syndrome model

Dr. Sam Pallerla

USA

Sam Pallerla, Ph.D., is Director of Global Drug Substance Commercialization at Vaxcyte, where he leads conjugate vaccine manufacturing and commercialization programs. He has more than 25 years of experience in vaccine and biologics process development, CMC strategy, technology transfer, clinical manufacturing, and commercial product development.
Prior to joining Vaxcyte, Dr. Pallerla held leadership roles at the International AIDS Vaccine Initiative.

Yu-Chen Hu

Taiwan